Nylaspeg (pegfilgrastim)

Where it stands

Nylaspeg (pegfilgrastim), from Qilu Pharma Spain S.L., received a positive CHMP opinion on 2026-06-25. The records list its status as "Authorised" but give no approval date. The only forward milestone is an expected European Commission (EC) decision on 2026-08-31.

That date is an estimate, not an official one. It is calculated as the CHMP opinion date plus 67 days, the standard Commission decision period. The status label and the missing approval date do not fit together. A CHMP opinion is a recommendation, and the marketing authorisation is only granted when the EC adopts its decision. On this record, the product should be treated as awaiting an EC decision unless an approval date is confirmed.

The indication is the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy for malignancy. Chronic myeloid leukaemia and myelodysplastic syndromes are excluded.

Regulatory pathway and designations

Nylaspeg carries a Biosimilar designation. In the EU, this means the product was assessed through the biosimilar pathway, in which the applicant shows that it is highly similar to an authorised reference biological medicine. The records do not name the reference product or describe the comparability data package, so this analysis does not cover them.

The same substance is already present in the market. Cavoley, Ziextenzo, Grasustek, Fulphila and Dyrupeg are listed as Authorised in the EU. Armlupeg is listed as Approved in the US. The records do not say who holds these products or whether they are biosimilars, and they do not link any of them to Nylaspeg's applicant. Nylaspeg would therefore enter an EU pegfilgrastim segment with several authorised products. Competitive implications cannot be drawn from the records.

Safety and pharmacovigilance

The records carry the Additional monitoring designation. In general, this means the product is subject to enhanced adverse-reaction reporting. The product information normally carries an inverted black triangle and a standard statement encouraging healthcare professionals and patients to report suspected side effects. The designation does not by itself indicate a specific safety concern.

The records contain no safety data, no risk management plan details and no post-authorisation commitments. This analysis therefore makes no statement on the product's safety profile, warnings or any additional risk-minimisation measures.

What to watch

The main event is the EC decision, estimated at 2026-08-31. Readers should confirm the actual decision date and the final authorisation text against official EU sources. The estimate may differ from the actual date, and the records currently show no approval date.

Once the decision is published, the useful items to check are the final product information, including the additional-monitoring wording, and any conditions attached to the authorisation. The records do not contain these items.